Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 22, Number 10—October 2016
Dispatch

Persistence of Antibodies against Middle East Respiratory Syndrome Coronavirus

Daniel C. PayneComments to Author , Ibrahim Iblan, Brian Rha, Sultan Alqasrawi, Aktham Haddadin, Mohannad Al Nsour, Tarek Alsanouri, Sami Sheikh Ali, Jennifer Harcourt, Congrong Miao, Azaibi Tamin, Susan I. Gerber, Lia M. Haynes, and Mohammad Mousa Al Abdallat
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (D.C. Payne, B. Rha, J. Harcourt, C. Miao, A. Tamin, S.I. Gerber, L.M. Haynes); Jordan Field Epidemiology Training Program, Amman, Jordan (I. Iblan); Jordan Ministry of Health, Amman (S. Alqasraw, A. Haddadin, T. Alsanouri, S. Sheikh Ali, M.M. Al Abdallat); Eastern Mediterranean Public Health Network, Amman (M. Al Nsour, T. Alsanouri)

Main Article

Figure

Neutralizing antibody titers against Middle East respiratory syndrome coronavirus (Hu/Jordan-N3/2012 strain) among 7 surviving case-patients at 13 and 34 months after the 2012 outbreak in Jordan. Patient numbers match those in the Table.

Figure. Neutralizing antibody titers against Middle East respiratory syndrome coronavirus (Hu/Jordan-N3/2012 strain) among 7 surviving case-patients at 13 and 34 months after the 2012 outbreak in Jordan. Patient numbers match those in the Table.

Main Article

Page created: September 20, 2016
Page updated: September 20, 2016
Page reviewed: September 20, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external